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Editorial
It's almost a decade since the whole genome sequence of
the tubercle bacillus M. tuberculosis was completed. The
genome sequence of tuberculosis (TB) bacteria has
opened various new avenues for studying biology of TB as
well as heralded major funding possibilities for research-
ers worldwide. However, it is pathetic to realize that we do
not have ready a 'promising' new drug target, a 'perfect'
vaccine candidate or a 'gold standard' diagnostic marker
as yet, for this dreaded pestilence. Countries like India are
worst sufferers of such a disappointingly delayed fruit of
post-genomic TB research and technology. Nonetheless,
significant benefits arising in terms of exploratory genom-
ics have helped the clinical cause of tracking and analyz-
ing the strains of epidemic potential. Gutierrez and
colleagues [1] in a recently reported multicentric research
based on genotyping of TB strains prevalent in modern
day India pointed to reservoirs of the ancestral strains,
which continue to predominate throughout the popula-
tion. Sujatha Narayanan from the Tuberculosis Research
Centre in Chennai echoed similar scenario for Tamil
Nadu area in the recently held 8th Congress of Molecular
Epidemiology and Evolutionary Genetics of Infectious
Diseases (MEEGID) at Bangkok in Thailand [2].
M. tuberculosis is a millennia old pestilence (perhaps since
more than 10, 000 BC) that continues to haunt the popu-
lation here. Genotyping of patient isolates through the
repertoire of variable-number tandem repeats (VNTRs)
portrayed  M. tuberculosis strain diversity in India. A
genomic signature, called as tuberculosis specific deletion
1 (TbD1), a chunk of DNA whose presence determines the
ancestral M. tuberculosis [3], a geno-family of possibly low
disseminating strains as compared to some of the very
highly spreading and expanding strains such as the Beijing
types [4,5]. Predominance of the ancestral strains possibly
suggests that India has been the ancient reservoir for TB in
the continent [1].
The ancestral strains bear seemingly important benefits
for the TB control programs in India. More importantly, as
a result of their adaptive evolution, the pathology trig-
gered by them may not be lethal. This analogy derives sup-
port from a series of laboratory animal experiments
pioneered by D. A. Mitchison in the early seventies show-
ing majority of the South Indian strains caused low grade
pathology [6,7]. Given the reportedly highest proportion
of ancestral strains in the South, we may hypothesize that
Mitchison's 'less virulent' bacteria were most probably the
bacilli of ancestral (TbD1+) group. This needs to be fur-
ther investigated. Also, it is speculated that such strains
disseminate less rapidly than the modern types possibly
due to a 'genomic load' of unshed TbD1 – thus an advan-
tage for local transmission dynamics. Consequently, these
strains might be comparatively less prone to acquisition
of resistance to antimicrobials – another advantage.
But the country is now seeing slow but gradual rise of Bei-
jing geno-family of strains that might out-compete the
ancestral types. The outcome could be hastened as India is
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witnessing a steep rise in the number of human immuno-
deficiency virus (HIV) cases, exceeding South Africa in
prevalence, with an estimated 5.7 million cases [8]. Syn-
ergy of TB, lead predominantly by the Beijing strains, with
HIV, threatens a series of outbreaks in several years to
come. With fast spreading HIV, local advantages due to
ancestral bacilli, in terms of adaptation, and possibly
'reduced virulence' might be ruined; HIV through deplet-
ing the host immune cells disregards any such advantages.
Although Beijing strains are not an immediate threat,
there is a danger that they might predominate in due
course if their dissemination dynamics change with
enhanced HIV transmission. Also, their link with several
outbreaks of drug resistant tuberculosis worldwide sug-
gests a genetically encoded propensity to acquire multi-
drug resistance as they spread and cross through their
host. It is clear that there is an ongoing transmission of
Beijing in India for which published reference is currently
meager, but individual labs have records based on geno-
typing on limited to moderately large sample sizes. None-
theless, there are incidences of Beijing being reported up
to as high as 30% from Mumbai [9], but it is still 8–10%
in Delhi [1,10]. Transmission of Beijing strains is more
likely to be facilitated with recent economic activity due to
a boom in the Information Technology (IT) and commu-
nication sectors where affordable air-travel has facilitated
frequent movement of especially younger population,
across cities.
It has been widely believed that India with its vast human
resource in healthcare, with DOTS coverage penetrating
almost countrywide, and a large national TB control pro-
gram, is all set to tackle the pestilence. We caution, to pre-
pare for the threat of institutionalized outbreaks
perpetuated by newly emerging and expanding strains in
synergy with HIV, that is probably looming large. It is true
that dedicated strain-typing facilities to monitor emer-
gence and preponderance of aggressive and non-aggres-
sive strains are almost non-existent here and epidemic-
forecasting systems therefore, would be difficult and
tough to devise. In view of this, it will be highly appropri-
ate to monitor carefully the comparative spread dynamics
of M. tuberculosis lineages in different settings through a
nationwide surveillance and response strategy on the lines
of the Centers for Disease Control and Prevention (CDC),
of the USA.
A European equivalent of CDC has been recently shaped
in Stockholm, thanks to the efforts championed by Michel
Tibayrenc, from the IRD in Montpellier, France. It took
quite long for Tibayrenc to muster the support of several
scientific organizations, attention of the policy makers,
and finally of politicians before his idea of European CDC
was approved in April 2004 under the new European leg-
islation. After European CDC, do we need an Indian
CDC? The answer is definitely 'yes' because India simply
does not have a sophisticated and focussed public health
laboratory system for dynamic epidemic surveillance and
disease forecasting. In a country that requires more effec-
tive surveillance of disease, better responses to epidemics,
and better disease prevention, such a new Centre, a possi-
ble networking hub of hundreds of public health labora-
tories, will play a central role in the context of preventing
the HIV-TB pandemic.
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